ClinicalTrials.gg
TerminatedNCT00845832Updated Dec 24, 2014Results posted

A Study of Combination Treatment With MabThera (Rituximab) and RoActemra (Tocilizumab) Versus RoActemra in Patients With Rheumatoid Arthritis With an Incomplete Response to Methotrexate

A Phase 2 interventional study of Placebo and rituximab [MabThera/Rituxan] in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Terminated at 24 sites in 8 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-12-24.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Why this study was terminated
The study was terminated early because of a related decision to stop the development of ocrelizumab in rheumatoid arthritis.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 63 studies testing rituximab in Arthritis, Rheumatoid — 5 open to participants now, 6 under way, 1 of them phase 3. Rituximab · Arthritis, Rheumatoid.

Enrollment
53rd of 63
24 · median 159
Started
2009
with 1 other
Phase 2
11 of 63
1 open now
Registered
24th of 63
by date
Lead sponsor
20 of 63
Hoffmann-La Roche

Among the 63 studies testing rituximab in Arthritis, Rheumatoid, this one is the 53rd largest by enrollment, is one of 2 that started in 2009, is one of 11 in phase 2, and was the 24th registered.

Arthritis, Rheumatoid

3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 63 studies testing rituximab in Arthritis, Rheumatoid are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing rituximab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This 2 part study will investigate the safety, tolerability and efficacy of MabT hera in combination with RoActemra in patients with active rheumatoid arthritis despite a stable dose of methotrexate. In Part 1 of the study, patients will be randomized to receive either MabThera 0.5g iv or placebo on days 1 and 15, follo wed by RoActemra at one of the ascending doses between 2mg/kg and 8mg/kg at week s 4, 8 and 12 (MabThera arm) or 8mg/kg (placebo arm). In Part 2, additional pati ents will be randomized to one of 2 groups to receive MabThera 0.5g on days 1 an d 15 followed by the selected dose (from Part 1)of RoActemra at weeks 4, 8 and 1 2, or placebo on days 1 and 15 followed by RoActemra 8mg/kg at weeks 4,8 and 12.

All patients will then be eligible to receive extension treatment withRoActemra every 4 weeks. The anticipated time on study treatment is 12 months, and the tar get sample size is \<100 individuals.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients, 18-65 years of age;
  • rheumatoid arthritis, functional status I-III;
  • SJC>=4 (28 joint count) and TJC>=4 (28 joint count) at screening and baseline;
  • RF and/or anti-CCP positive;
  • may have failed up to 1 approved anti-TNF agent (infliximab, etanercept or adalimumab);
  • inadequate response to methotrexate, at a dose of 7.5-25mg weekly for at least 12 weeks, at a stable dose for past 4 weeks.

Exclusion criteria

Exclusion Criteria:

  • rheumatic disease other than rheumatoid arthritis, or significant systemic involvement secondary to rheumatoid arthritis;
  • history of, or current, inflammatory joint disease other than rheumatoid arthritis;
  • diagnosis of juvenile idiopathic arthritis and/or rheumatoid arthritis before age 16;
  • significant cardiac or pulmonary disease;
  • previous treatment with any biologic agent for rheumatoid arthritis (other than infliximab, etanercept or adalimumab).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    1

    Drug: rituximab [MabThera/Rituxan] · Drug: tocilizumab [RoActemra/Actemra]

  • Active comparator
    2

    Drug: Placebo · Drug: tocilizumab [RoActemra/Actemra]

Interventions

  • DrugPlacebo

    iv on days 1 and 15 (Parts 1 and 2)

  • Drugrituximab [MabThera/Rituxan]

    Drug page: Rituximab

    0.5g iv on days 1 and 15 (Parts 1 and 2)

  • Drugtocilizumab [RoActemra/Actemra]

    Drug page: Tocilizumab

    2mg/kg-8mg/kg iv in Part 1 and selected dose in Part 2, on weeks 4, 8 and 12---Arm 1\\n8mg/kg iv on weeks 4,8 and 12 (Parts 1 and 2)--- Arm 2

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Low Disease Activity (LDA) at Week 16 Assessed Using Disease Activity Score Based on 28 Joint Count and Erythrocyte Sedimentation Rate (DAS28-ESR)

    The Disease Activity Score based on 28 joint count (DAS28) and Erythrocyte Sedimentation Rate (ESR), is a measure of the participant's disease activity. It is based on the Tender Joint Count (TJC \[28 joints\]), Swollen Joint Count (SJC \[28 joints\]), participant's global assessment of disease activity (PtGA) Visual Analog Scale (VAS) in millimeters (mm), and ESR in millimeters per hour (mm/hour). DAS28-ESR scores range from 0 - 10. Definition of LDA was based on DAS28-ESR scores. To achieve LDA the DAS28-ESR had to be (less than or equal to) ≤ 3.2. DAS28-ESR equals (=) (0.56 times (\*) (square root)√ TJC plus (+) (0.28 \* √ SJC + (0.70 \* ln(ESR))+(0.014 \* (Global Health) GH) Where: TJC = based on 28 joints SJC = based on 28 joints ESR = erythrocyte sedimentation rate in mm/hour GH = participant's global assessment of disease activity ln = natural log

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants Achieving Remission at Week 16 Assessed Using DAS28-ESR

    The DAS28-ESR score is a measure of the participant's disease activity. It is based on the TJC (28 joints), SJC (28 joints), participant's global assessment of disease activity (mm), and ESR (mm/hour). DAS28-ESR is expressed on a unit on a scale with the minimum score=0 (best) to maximum score=10 (worst). Remission was defined as DAS28-ESR less than (\<) 2.6

    Time frame: Week 16

  2. Percentage of Participants by European League Against Rheumatism (EULAR) Response Category at Week 16

    DAS28-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline (greater than) \>1.2 with DAS28 ≤3.2; moderate responders: change from baseline \>1.2 with DAS28 \>3.2 to ≤5.1 or DAS28-ESR \>5.1 or change from baseline \>0.6 to ≤1.2 with DAS28 ≤5.1; nonresponders: change from baseline ≤0.6 or change from baseline \>0.6 and ≤1.2 with DAS28 \>5.1.

    Time frame: Week 16

  3. Change From Baseline in DAS28-ESR

    The DAS28-ESR score is a measure of the participant's disease activity. It is based on the TJC (28 joints), SJC (28 joints), participant's global assessment of disease activity (mm), and ESR (mm/hour). DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). DAS28-ESR scores were calculated as follows: DAS28-ESR = (0.56 \* √TJC)+(0.28 \* √SJC)+(0.70 \* ln(ESR))+(0.014 \* GH). No imputation used for tender and swollen joint counts, ESR, and patient's global assessment of disease activity VAS.

    Time frame: Weeks 4, 8, 12, 16, 20, 24, 32, 40 and 48

  4. Clinical Disease Activity Index Scores

    The Clinical Disease Activity Index (CDAI) score was calculated according to the following formula: CDAI = SJC + TJC + GH/10 + EGA/10 Where: SJC = swollen joint count based on 28 joints; TJC = tender joint count based on 28 joints; GH = Participant's global assessment of disease activity; EGA = evaluator's (physician's) global assessment of disease activity. CDAI scores range from 0-76 and the following cut-off points for different disease activity states have been used: high disease activity \>22; moderate disease activity \>10 and ≤22; LDA \>2.8 and ≤10; and remission ≤ 2.8. No imputation used for TJC, SJC, Patient's Global Assessment of Disease Activity VAS and Physicians global assessment of disease activity VAS.

    Time frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 32, 40 and 48

  5. Simplified Disease Activity Index (SDAI) Scores

    The SDAI is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), Participant and Physician assessed global disease activity (assessed on 0-100 mm VAS; higher scores = greater affection due to disease activity), and ESR (mm/hour). SDAI total score ranged from 0 to 86. Higher scores indicated greater disease activity.

    Time frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 32, 40, and 48

  6. Change From Baseline to Week 48 in SJC and TJC

    An assessment of 28 joints for swelling and tenderness will be made. Joints will be assessed and classified as swollen (1)/not swollen (0) and tender(1)/not tender (0) by pressure and joint manipulation on physical examination. Joint prosthesis, arthrodesis or fused joints were not taken into consideration for swelling or tenderness. The 28 joints assessed comprise shoulders (2 joints), elbows (2 joints), wrists (2 joints), metacarpophalangeal joints on digits 1-5 (10 joints), interphalangeal on digit 1 (2 joints), proximal interphalangeal joints on digits 2-5 (8 joints), and knees (2 joints).

    Time frame: Baseline and Week 48

  7. Change From Baseline to Week 48 in Health Assessment Questionnaire (HAQ)

    The Stanford Health Assessment Questionnaire disability index specific for rheumatoid arthritis was completed by the participants for efficacy assessments.

    Time frame: Baseline and Week 48

  8. Change From Baseline to Week 48 in C-Reactive Protein (CRP)

    CRP is an acute phase reactant and is a measure of inflammation.

    Time frame: Baseline and Week 48

  9. Change From Baseline to Week 48 in ESR

    ESR is an acute phase reactant and is a measure of inflammation.

    Time frame: Baseline and Week 48

  10. Change From Baseline to Week 48 in Physician's Global Assessment of Disease Activity

    Physician Global Assessment of Disease Activity was measured on a 0 to 100 mm VAS, with 0 mm = no disease activity and 100 mm= maximum disease activity. The physician marked the line according to their assessment and the distance from the left edge was measured.

    Time frame: Baseline and Week 48

  11. Change From Baseline to Week 48 in Participant's Global Assessment of Disease Activity

    Participant's Global Assessment of Disease Activity was measured on a 0 to 100 mm VAS, with 0 mm = no disease activity and 100 mm = maximum disease activity. The participant marked the line according to their assessment and the distance from the left edge was measured.

    Time frame: Baseline and Week 48

  12. Change From Baseline to Week 48 in Participant's Assessment of Pain

    Participant's Global Assessment of Disease Activity was measured on a 0 to 100 mm VAS, with 0 mm = no pain and 100 mm = maximum pain. The participant marked the line according to their assessment and the distance from the left edge was measured.

    Time frame: Baseline and Week 48

07

Results

Posted Dec 24, 2014

Participant flow

Treatment Period
Participant flow — Treatment Period
MilestonePlacebo + Tocilizumab (TCZ) 8 Milligrams Per Kilogram (mg/kg)Rituximab (0.5 Grams [g]) + TCZ (2 mg/kg)Rituximab (0.5 g) + TCZ (4 mg/kg)
Started41010
Completed3710
Not completed130
Withdrew: Adverse event020
Withdrew: Protocol violation110
Safety Follow-Up
Participant flow — Safety Follow-Up
MilestonePlacebo + Tocilizumab (TCZ) 8 Milligrams Per Kilogram (mg/kg)Rituximab (0.5 Grams [g]) + TCZ (2 mg/kg)Rituximab (0.5 g) + TCZ (4 mg/kg)
Started3912
Completed2912
Not completed100
Withdrew: Withdrawal by subject100
Extended Safety Follow-Up
Participant flow — Extended Safety Follow-Up
MilestonePlacebo + Tocilizumab (TCZ) 8 Milligrams Per Kilogram (mg/kg)Rituximab (0.5 Grams [g]) + TCZ (2 mg/kg)Rituximab (0.5 g) + TCZ (4 mg/kg)
Started257
Completed250
Not completed007
Withdrew: Withdrawal by subject007

Outcome measures

PrimaryPercentage of Participants Achieving Low Disease Activity (LDA) at Week 16 Assessed Using Disease Activity Score Based on 28 Joint Count and Erythrocyte Sedimentation Rate (DAS28-ESR)

The Disease Activity Score based on 28 joint count (DAS28) and Erythrocyte Sedimentation Rate (ESR), is a measure of the participant's disease activity. It is based on the Tender Joint Count (TJC \[28 joints\]), Swollen Joint Count (SJC \[28 joints\]), participant's global assessment of disease activity (PtGA) Visual Analog Scale (VAS) in millimeters (mm), and ESR in millimeters per hour (mm/hour). DAS28-ESR scores range from 0 - 10. Definition of LDA was based on DAS28-ESR scores. To achieve LDA the DAS28-ESR had to be (less than or equal to) ≤ 3.2. DAS28-ESR equals (=) (0.56 times (\*) (square root)√ TJC plus (+) (0.28 \* √ SJC + (0.70 \* ln(ESR))+(0.014 \* (Global Health) GH) Where: TJC = based on 28 joints SJC = based on 28 joints ESR = erythrocyte sedimentation rate in mm/hour GH = participant's global assessment of disease activity ln = natural log

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Low Disease Activity (LDA) at Week 16 Assessed Using Disease Activity Score Based on 28 Joint Count and Erythrocyte Sedimentation Rate (DAS28-ESR)
percentage of participantsPlacebo + TCZ (8 mg/kg)Rituximab (0.5 g) + TCZ (2 mg/kg)Rituximab (0.5 g) + TCZ (4 mg/kg)
Percentage of Participants Achieving Low Disease Activity (LDA) at Week 16 Assessed Using Disease Activity Score Based on 28 Joint Count and Erythrocyte Sedimentation Rate (DAS28-ESR)50.011.120.0
SecondaryPercentage of Participants Achieving Remission at Week 16 Assessed Using DAS28-ESR

The DAS28-ESR score is a measure of the participant's disease activity. It is based on the TJC (28 joints), SJC (28 joints), participant's global assessment of disease activity (mm), and ESR (mm/hour). DAS28-ESR is expressed on a unit on a scale with the minimum score=0 (best) to maximum score=10 (worst). Remission was defined as DAS28-ESR less than (\<) 2.6

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Remission at Week 16 Assessed Using DAS28-ESR
percentage of participantsPlacebo + TCZ (8 mg/kg)Rituximab (0.5 g) + TCZ (2 mg/kg)Rituximab (0.5 g) + TCZ (4 mg/kg)
Percentage of Participants Achieving Remission at Week 16 Assessed Using DAS28-ESR0.00.010.0
SecondaryPercentage of Participants by European League Against Rheumatism (EULAR) Response Category at Week 16

DAS28-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline (greater than) \>1.2 with DAS28 ≤3.2; moderate responders: change from baseline \>1.2 with DAS28 \>3.2 to ≤5.1 or DAS28-ESR \>5.1 or change from baseline \>0.6 to ≤1.2 with DAS28 ≤5.1; nonresponders: change from baseline ≤0.6 or change from baseline \>0.6 and ≤1.2 with DAS28 \>5.1.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants by European League Against Rheumatism (EULAR) Response Category at Week 16
percentage of participantsPlacebo + TCZ (8 mg/kg)Rituximab (0.5 g) + TCZ (2 mg/kg)Rituximab (0.5 g) + TCZ (4 mg/kg)
No Response0.022.211.1
Moderate Response50.066.766.7
Good Response50.011.122.2
SecondaryChange From Baseline in DAS28-ESR

The DAS28-ESR score is a measure of the participant's disease activity. It is based on the TJC (28 joints), SJC (28 joints), participant's global assessment of disease activity (mm), and ESR (mm/hour). DAS28-ESR is expressed as a score on a scale with the minimum score=0 (best) to maximum score=10 (worst). DAS28-ESR scores were calculated as follows: DAS28-ESR = (0.56 \* √TJC)+(0.28 \* √SJC)+(0.70 \* ln(ESR))+(0.014 \* GH). No imputation used for tender and swollen joint counts, ESR, and patient's global assessment of disease activity VAS.

Time frame:
Weeks 4, 8, 12, 16, 20, 24, 32, 40 and 48
Reported as:
Mean · units on a scale
Change From Baseline in DAS28-ESR
units on a scalePlacebo + TCZ (8 mg/kg)Rituximab (0.5 g) + TCZ (2 mg/kg)Rituximab (0.5 g) + TCZ (4 mg/kg)
Week 4 (n=4,9,10)-1.9 ± 1.73-0.7 ± 1.44-1.0 ± 0.72
Week 8 (n=4,10,10)-2.7 ± 0.55-0.5 ± 1.33-1.9 ± 1.31
Week 12 (n=4,10,9)-2.7 ± 0.57-1.2 ± 1.60-2.3 ± 1.36
Week 16 (n=4,9,9)-3.0 ± 0.80-1.8 ± 1.44-2.3 ± 1.25
Week 20 (n=4,9,9)-3.6 ± 0.70-2.2 ± 1.16-2.7 ± 1.45
Week 24 (n=4,9,8)-3.5 ± 1.28-2.2 ± 1.14-2.9 ± 1.34
Week 32 (n=4,9,8)-2.6 ± 1.62-3.1 ± 1.92-3.3 ± 1.83
Week 40 (n=3,8,8)-2.6 ± 1.24-2.2 ± 1.63-2.7 ± 1.02
Week 48 (n=4,8,7)-3.3 ± 1.84-2.9 ± 1.50-3.0 ± 1.24
SecondaryClinical Disease Activity Index Scores

The Clinical Disease Activity Index (CDAI) score was calculated according to the following formula: CDAI = SJC + TJC + GH/10 + EGA/10 Where: SJC = swollen joint count based on 28 joints; TJC = tender joint count based on 28 joints; GH = Participant's global assessment of disease activity; EGA = evaluator's (physician's) global assessment of disease activity. CDAI scores range from 0-76 and the following cut-off points for different disease activity states have been used: high disease activity \>22; moderate disease activity \>10 and ≤22; LDA \>2.8 and ≤10; and remission ≤ 2.8. No imputation used for TJC, SJC, Patient's Global Assessment of Disease Activity VAS and Physicians global assessment of disease activity VAS.

Time frame:
Baseline and Weeks 4, 8, 12, 16, 20, 24, 32, 40 and 48
Reported as:
Mean · units on a scale
Clinical Disease Activity Index Scores
units on a scalePlacebo + TCZ (8 mg/kg)Rituximab (0.5 g) + TCZ (2 mg/kg)Rituximab (0.5 g) + TCZ (4 mg/kg)
Baseline (n=4, 10, 10)37.7 ± 4.5936.4 ± 9.1633.0 ± 7.69
Week 4 (n=4, 8, 10)21.2 ± 14.1923.4 ± 12.3820.0 ± 6.97
Week 8 (n=4,10,10)14.6 ± 4.3829.4 ± 14.9115.5 ± 9.96
Week 12 (n=4,10, 9)16.3 ± 10.5223.2 ± 12.4713.4 ± 8.40
Week 16 (n=4,10, 9)9.5 ± 5.7019.5 ± 15.4212.7 ± 8.32
Week 20 (n=4, 8, 9)10.8 ± 4.4615.4 ± 7.7611.6 ± 6.64
Week 24 (n=4, 9, 8)9.2 ± 6.7112.6 ± 3.9810.9 ± 5.47
Week 32 (n=4, 9, 8)15.2 ± 10.4211.5 ± 13.149.3 ± 9.42
Week 40 (n=3, 8, 8)20.3 ± 8.3517.9 ± 16.4011.8 ± 5.31
Week 48 (n=4, 7, 8)11.6 ± 10.1112.8 ± 12.157.1 ± 6.41
SecondarySimplified Disease Activity Index (SDAI) Scores

The SDAI is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), Participant and Physician assessed global disease activity (assessed on 0-100 mm VAS; higher scores = greater affection due to disease activity), and ESR (mm/hour). SDAI total score ranged from 0 to 86. Higher scores indicated greater disease activity.

Time frame:
Baseline and Weeks 4, 8, 12, 16, 20, 24, 32, 40, and 48

No measurements were reported for this outcome.

SecondaryChange From Baseline to Week 48 in SJC and TJC

An assessment of 28 joints for swelling and tenderness will be made. Joints will be assessed and classified as swollen (1)/not swollen (0) and tender(1)/not tender (0) by pressure and joint manipulation on physical examination. Joint prosthesis, arthrodesis or fused joints were not taken into consideration for swelling or tenderness. The 28 joints assessed comprise shoulders (2 joints), elbows (2 joints), wrists (2 joints), metacarpophalangeal joints on digits 1-5 (10 joints), interphalangeal on digit 1 (2 joints), proximal interphalangeal joints on digits 2-5 (8 joints), and knees (2 joints).

Time frame:
Baseline and Week 48

No measurements were reported for this outcome.

SecondaryChange From Baseline to Week 48 in Health Assessment Questionnaire (HAQ)

The Stanford Health Assessment Questionnaire disability index specific for rheumatoid arthritis was completed by the participants for efficacy assessments.

Time frame:
Baseline and Week 48

No measurements were reported for this outcome.

SecondaryChange From Baseline to Week 48 in C-Reactive Protein (CRP)

CRP is an acute phase reactant and is a measure of inflammation.

Time frame:
Baseline and Week 48

No measurements were reported for this outcome.

SecondaryChange From Baseline to Week 48 in ESR

ESR is an acute phase reactant and is a measure of inflammation.

Time frame:
Baseline and Week 48

No measurements were reported for this outcome.

SecondaryChange From Baseline to Week 48 in Physician's Global Assessment of Disease Activity

Physician Global Assessment of Disease Activity was measured on a 0 to 100 mm VAS, with 0 mm = no disease activity and 100 mm= maximum disease activity. The physician marked the line according to their assessment and the distance from the left edge was measured.

Time frame:
Baseline and Week 48

No measurements were reported for this outcome.

SecondaryChange From Baseline to Week 48 in Participant's Global Assessment of Disease Activity

Participant's Global Assessment of Disease Activity was measured on a 0 to 100 mm VAS, with 0 mm = no disease activity and 100 mm = maximum disease activity. The participant marked the line according to their assessment and the distance from the left edge was measured.

Time frame:
Baseline and Week 48

No measurements were reported for this outcome.

SecondaryChange From Baseline to Week 48 in Participant's Assessment of Pain

Participant's Global Assessment of Disease Activity was measured on a 0 to 100 mm VAS, with 0 mm = no pain and 100 mm = maximum pain. The participant marked the line according to their assessment and the distance from the left edge was measured.

Time frame:
Baseline and Week 48

No measurements were reported for this outcome.

Adverse events

Collected over Adverse Events were recorded throughout the study from the date of first study drug administration until 48 weeks of treatment period and for those in the Safety follow up population until the end of follow up period.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo + TCZ (8 mg/kg)—1/3 (33.3%)3/3 (100%)
Rituximab (0.5 g) + TCZ (2 mg/kg)—2/9 (22.2%)9/9 (100%)
Rituximab (0.5 g) + TCZ (4 mg/kg)—3/12 (25%)11/12 (91.7%)
Most frequent serious events
Most frequent serious events
EventPlacebo + TCZ (8 mg/kg)Rituximab (0.5 g) + TCZ (2 mg/kg)Rituximab (0.5 g) + TCZ (4 mg/kg)
Rotator cuff syndromeMusculoskeletal and connective tissue disorders1/30/90/12
Infusion related reactionGeneral disorders0/31/90/12
PneumonitisRespiratory, thoracic and mediastinal disorders0/31/90/12
PneumoniaInfections and infestations0/31/90/12
Chest painGeneral disorders0/30/91/12
Large intestinal ulcer haemorrhageGastrointestinal disorders0/30/91/12
Umbilical herniaGastrointestinal disorders0/30/91/12
Most frequent other events
Showing 10 of 63
Most frequent other events
EventPlacebo + TCZ (8 mg/kg)Rituximab (0.5 g) + TCZ (2 mg/kg)Rituximab (0.5 g) + TCZ (4 mg/kg)
NauseaGastrointestinal disorders2/30/91/12
Oedema peripheralGeneral disorders2/31/90/12
Upper respiratory tract infectionInjury, poisoning and procedural complications0/33/93/12
NasopharyngitisInfections and infestations1/30/92/12
Acute tonsillitisInfections and infestations1/30/90/12
DyspepsiaGastrointestinal disorders0/33/90/12
Infusion related reactionGeneral disorders0/33/91/12
Back painMusculoskeletal and connective tissue disorders1/31/91/12
Photosensitivity reactionSkin and subcutaneous tissue disorders1/30/90/12
DizzinessNervous system disorders1/30/90/12

Baseline characteristics

Safety population: All participants who were randomized and received any part of an infusion of study medication; participants who received the incorrect therapy from that intended were summarized in the group according to the therapy actually received for the majority of the time through Week 48.

Age, Continuous
Age, Continuous(years)Placebo + TCZ (8 mg/kg)Rituximab (0.5 g) + TCZ (2 mg/kg)Rituximab (0.5 g) + TCZ (4 mg/kg)Total
Mean41.3 ± 11.0248.2 ± 10.5050.0 ± 6.9748.3 ± 8.94
Sex: Female, Male
Sex: Female, Male(Participants)Placebo + TCZ (8 mg/kg)Rituximab (0.5 g) + TCZ (2 mg/kg)Rituximab (0.5 g) + TCZ (4 mg/kg)Total
Female371020
Male0224
08

Study locations

24 sites
  • Le Kremlin Bicetre, 94275, France
  • Montpellier, 34295, France
  • Paris, 75679, France
  • Strasbourg, 67098, France
  • Berlin, 10117, Germany
  • Berlin, 14059, Germany
  • Heidelberg, 69120, Germany
  • Köln, 50924, Germany
  • Wuerzburg, 97080, Germany
  • Athens, 15121, Greece
  • Thessaloniki, 54636, Greece
  • Amsterdam, 1105 AZ, Netherlands
  • Leiden, 2333 ZA, Netherlands
  • Bytom, 41-902, Poland
  • Lublin, 20-607, Poland
  • Poznan, 60-218, Poland
  • Santander, Cantabria 39008, Spain
  • Santiago de Compostela, La Coruña 15706, Spain
  • Madrid, 28007, Spain
  • Sevilla, 41009, Spain
  • Bern, 3010, Switzerland
  • Lausanne, 1011, Switzerland
  • Newcastle Upon Tyne, NE1 4LP, United Kingdom
  • Southampton, SO16 6YD, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2014, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2009
First posted
Feb 18, 2009
Start
Mar 2009
Primary completionActual
Mar 2013
CompletionActual
Mar 2013
Results first posted
Dec 24, 2014
Last update
Dec 24, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00845832
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Feb 18, 2009
Start date
Mar 2009
Primary completion
Mar 2013
Completion
Mar 2013
Results posted
Dec 24, 2014
Last update
Dec 24, 2014

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion